Neoantigen Synthetic Peptide Vaccine for Multiple Myeloma Elicits T Cell Immunity in a Pre-Clinical Model

被引：0
|
作者：
Bekri, Selma
Uduman, Mohamed
Gruenstein, Diana
Mei, Anna Huo-Chang
Tung, Kaity
Rodney-Sandy, Reunet
Bogen, Bjarne
Buell, Jennifer
Stein, Robert
Doherty, Kaitlin
Findeis, Mark
Morin, Benjamin
Joshi, Bishnu
Tanne, Antoine
Castle, John
Levey, Daniel
Cho, Hearn Jay
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1868
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Strategies for reconstituting and boosting T cell-based immunity following haematopoietic stem cell transplantation: pre-clinical and clinical approaches
    Ann P. Chidgey
    Natalie Seach
    Jarrod Dudakov
    Maree V. Hammett
    Richard L. Boyd
    Seminars in Immunopathology, 2008, 30 : 457 - 477
  • [22] Strategies for reconstituting and boosting T cell-based immunity following haematopoietic stem cell transplantation: pre-clinical and clinical approaches
    Chidgey, Ann P.
    Seach, Natalie
    Dudakov, Jarrod
    Hammett, Maree V.
    Boyd, Richard L.
    SEMINARS IN IMMUNOPATHOLOGY, 2008, 30 (04) : 457 - 477
  • [23] Protein vaccine NVX-CoV2373 elicits functional T cell immunity
    Zhou, Pengcheng
    JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (19):
  • [24] Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
    Drent, Esther
    Groen, Richard W. J.
    Noort, Willy A.
    Themeli, Maria
    van Bueren, Jeroen J. Lammerts
    Parren, Paul W. H. I.
    Kuball, Jurgen
    Sebestyen, Zsolt
    Yuan, Huipin
    de Bruijn, Joost
    van de Donk, Niels W. C. J.
    Martens, Anton C. M.
    Lokhorst, Henk M.
    Mutis, Tuna
    HAEMATOLOGICA, 2016, 101 (05) : 616 - 625
  • [25] Pre-clinical evaluation of candidate antibodies for targeted radiotherapy for patients with multiple myeloma.
    Orchard, KH
    Cooper, MS
    Wijdenes, J
    Borchardt, P
    Quadri, SM
    Buscombe, JR
    Hilson, AJ
    Mehta, A
    Prentice, HG
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 117P - 118P
  • [26] Melphalan and XPO1 inhibition are synergistic in pre-clinical models of multiple myeloma
    Turner, Joel G.
    Dawson, Jana L.
    Sullivan, Daniel M.
    CANCER RESEARCH, 2016, 76
  • [27] Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma
    de Brito, Luis R.
    Batey, Mike A.
    Zhao, Yan
    Squires, Matt S.
    Maitland, Helen
    Leung, Hing Y.
    Hall, Andrew G.
    Jackson, Graham
    Newell, David R.
    Irving, Julie A. E.
    LEUKEMIA RESEARCH, 2011, 35 (09) : 1233 - 1240
  • [28] mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer
    Cafri, Gal
    Gartner, Jared J.
    Zaks, Tal
    Hopson, Kristen
    Levin, Noam
    Paria, Biman C.
    Parkhurst, Maria R.
    Yossef, Rami
    Lowery, Frank J.
    Jafferji, Mohammad S.
    Prickett, Todd D.
    Goff, Stephanie L.
    McGowan, Christine T.
    Seitter, Samantha
    Shindorf, Mackenzie L.
    Parikh, Anup
    Chatani, Praveen D.
    Robbins, Paul F.
    Rosenberg, Steven A.
    JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (11): : 5976 - 5988
  • [29] Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma
    Bjorklund, Chad C.
    Amatangelo, Michael
    Chiu, Hsiling
    Kang, Jian
    Civardi, Tiziana
    Katz, Jessica
    Maciag, Paulo
    Hagner, Patrick
    Pourdehnad, Michael
    Bahlis, Nizar J.
    Richardson, Paul G.
    Thakurta, Anjan
    BLOOD, 2021, 138
  • [30] Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma
    Perumal, Deepak
    Imai, Naoko
    Lagana, Alessandro
    Finnigan, John
    Melnekoff, David
    Leshchenko, Violetta V.
    Solovyov, Alexander
    Madduri, Deepu
    Chari, Ajai
    Cho, Hearn Jay
    Dudley, Joel T.
    Brody, Joshua D.
    Jagannath, Sundar
    Greenbaum, Benjamin
    Gnjatic, Sacha
    Bhardwaj, Nina
    Parekh, Samir
    CLINICAL CANCER RESEARCH, 2020, 26 (02) : 450 - 464
12345